Keywords
Abstract
Parkinson kasalligi – dopaminergik neyronlarning nigrostriatal tizimda degeneratsiyalanishi bilan xarakterlanuvchi surunkali neyrodegenerativ kasallikdir. An’anaviy simptomatik terapiyalar kasallikning faqat klinik alomatlarini yengillashtiradi, ammo uning patogeneziga ta’sir ko‘rsatmaydi. So‘nggi yillarda gen terapiyasi va neyroprotektiv dori vositalari Parkinson kasalligini patogenetik jihatdan davolash yo‘nalishida muhim ilmiy yutuqlarni namoyon etmoqda. Ushbu maqolada AAV asosidagi gen terapiyalari, alpha-sinuklein patologiyasiga yo‘naltirilgan immunoterapiyalar, shuningdek LRRK2 va GBA genlariga asoslangan individual yondashuvlar tahlil qilinadi. Neyroinflammasiyani kamaytiruvchi vositalar va sun’iy intellekt asosidagi individual terapiya strategiyalari Parkinson kasalligini kompleks davolashda istiqbolli yondashuvlar sifatida ko‘rib chiqiladi.
References
1. Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912.
2. Palfi, S., Gurruchaga, J. M., Ralph, G. S., et al. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. The Lancet, 383(9923), 1138–1146.
3. Bartus, R. T., Weinberg, M. S., & Samulski, R. J. (2014). Parkinson’s disease gene therapy: success by design meets failure by efficacy. Molecular Therapy, 22(3), 487–497.
4. Mullin, S., Schapira, A. H. V. (2015). The genetics of Parkinson’s disease. British Medical Bulletin, 114(1), 39–52.
5. Poewe, W., Seppi, K., Tanner, C. M., et al. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.
6. Brundin, P., Dave, K. D., & Kordower, J. H. (2017). Therapeutic approaches to target alpha-synuclein pathology. Experimental Neurology, 298, 225–235.
7. Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson's Disease, 8(s1), S3–S8.